Prolight Diagnostics (PRLD) 주식 개요스웨덴에서 현장 진료 검사에 사용되는 진단 시스템을 개발하는 Prolight Diagnostics AB(publ)가 있습니다. 자세히 보기PRLD 펀더멘털 분석스노우플레이크 점수가치 평가1/6미래 성장0/6과거 실적0/6재무 건전성4/6배당0/6위험 분석cash runway 경력이 1년 미만입니다.지난 1년 동안 주주가 크게 희석되었습니다.지난 5년간 매년 수익이 37.7% 감소했습니다.의미 있는 시가총액이 없습니다(SEK153M)+ 위험 2건 추가모든 위험 점검 보기PRLD Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueSEK Current PriceSEK 12.460.6% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-135m222m2016201920222025202620282031Revenue SEK 221.7mEarnings SEK 29.5mAdvancedSet Fair ValueView all narrativesProlight Diagnostics AB (publ) 경쟁사Solution International NordicsSymbol: NGM:SINMarket cap: SEK 167.4mIntegrumSymbol: OM:INTEG BMarket cap: SEK 206.9mBoule DiagnosticsSymbol: OM:BOULMarket cap: SEK 131.3mArcomaSymbol: OM:ARCOMAMarket cap: SEK 123.9m가격 이력 및 성과Prolight Diagnostics 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가SEK 12.4652주 최고가SEK 052주 최저가SEK 0베타2.691개월 변동-22.90%3개월 변동-30.47%1년 변동-51.89%3년 변동-64.30%5년 변동-91.09%IPO 이후 변동-66.23%최근 뉴스 및 업데이트Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chairman of the board Fredrik Alpsten was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • Apr 22Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...분석 기사 • Dec 23Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...공시 • May 23Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million.Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million. Security Name: Shares Security Type: Common Stock Securities Offered: 501,492,480 Price\Range: SEK 0.2 Transaction Features: Rights OfferingRecent Insider Transactions Derivative • Oct 23CEO & Director exercised options to buy kr450k worth of stock.On the 18th of October, Ulf Bladin exercised options to buy 3m shares at a strike price of around kr0.12, costing a total of kr300k. This transaction amounted to 345% of their direct individual holding at the time of the trade. Since December 2023, Ulf has owned 724.64k shares directly. Company insiders have collectively bought kr358k more than they sold, via options and on-market transactions, in the last 12 months.New Risk • Oct 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr97.4m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 75% per year over the past 5 years. Shareholders have been substantially diluted in the past year (112% increase in shares outstanding). Market cap is less than US$10m (kr97.4m market cap, or US$9.48m). Minor Risk Revenue is less than US$5m (kr25m revenue, or US$2.4m).더 많은 업데이트 보기Recent updatesBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chairman of the board Fredrik Alpsten was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • Apr 22Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...분석 기사 • Dec 23Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...공시 • May 23Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million.Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million. Security Name: Shares Security Type: Common Stock Securities Offered: 501,492,480 Price\Range: SEK 0.2 Transaction Features: Rights OfferingRecent Insider Transactions Derivative • Oct 23CEO & Director exercised options to buy kr450k worth of stock.On the 18th of October, Ulf Bladin exercised options to buy 3m shares at a strike price of around kr0.12, costing a total of kr300k. This transaction amounted to 345% of their direct individual holding at the time of the trade. Since December 2023, Ulf has owned 724.64k shares directly. Company insiders have collectively bought kr358k more than they sold, via options and on-market transactions, in the last 12 months.New Risk • Oct 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr97.4m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 75% per year over the past 5 years. Shareholders have been substantially diluted in the past year (112% increase in shares outstanding). Market cap is less than US$10m (kr97.4m market cap, or US$9.48m). Minor Risk Revenue is less than US$5m (kr25m revenue, or US$2.4m).Reported Earnings • Aug 30Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr4.16m (up 32% from 2Q 2023). Net loss: kr11.2m (loss widened 40% from 2Q 2023).공시 • Jun 25Prolight Diagnostics and TTP Provides Update on MicroFlex DevelopmentProlight Diagnostics and TTP have developed the Point-of-Care system MicroFlex which brings the benefits of central-lab quality ELISA testing to more distributed environments with a compact and more user-friendly package.Reported Earnings • May 22First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr3.40m (down 2.7% from 1Q 2023). Net loss: kr8.93m (loss widened 18% from 1Q 2023).공시 • Apr 19Prolight Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024Prolight Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Apr 23, 2024공시 • Apr 10Prolight Diagnostics AB (publ), Annual General Meeting, May 14, 2024Prolight Diagnostics AB (publ), Annual General Meeting, May 14, 2024, at 13:00 Central European Standard Time. Location: Company’s office, Gasverksgatan 3 A, 222 29 Lund Sweden Agenda: To Establishment and approval of the voting list; to discuss Approval of the agenda; to discuss Election of one or two persons to verify the minutes; to Determination as to whether the Meeting has been duly convened; to Presentation of the annual report and the auditor’s report as well as the group accounts and the auditor’s report for the group for the financial year 2023; and to discuss other matters.New Risk • Mar 04New major risk - Revenue and earnings growthEarnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Market cap is less than US$10m (kr100.0m market cap, or US$9.69m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (kr19m revenue, or US$1.8m).New Risk • Feb 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 76% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Market cap is less than US$10m (kr100.9m market cap, or US$9.62m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (kr15m revenue, or US$1.5m).New Risk • Dec 13New major risk - Revenue and earnings growthEarnings have declined by 36% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr49m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (kr90.6m market cap, or US$8.67m). Minor Risk Revenue is less than US$5m (kr36m revenue, or US$3.5m).New Risk • Oct 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr83.8m (US$7.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (kr83.8m market cap, or US$7.53m). Minor Risk Revenue is less than US$5m (kr11m revenue, or US$1.0m).분석 기사 • Jul 14Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Jun 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (kr5.7m revenue, or US$538k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (kr120.8m market cap, or US$11.3m).Recent Insider Transactions • Jan 22Board Member recently bought kr172k worth of stockOn the 18th of January, Tobias Volker bought around 500k shares on-market at roughly kr0.34 per share. This transaction amounted to 82% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr184k more in shares than they have sold in the last 12 months.Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. No independent directors (6 non-independent directors). Director Maria Holmlund is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman of the Board Ingemar Kihlstrom was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • Nov 07Companies Like Prolight Diagnostics (NGM:PRLD) Can Afford To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...분석 기사 • Jul 06We Think Prolight Diagnostics (NGM:PRLD) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • Mar 09Companies Like Prolight Diagnostics (NGM:PRLD) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Is New 90 Day High Low • Feb 23New 90-day low: kr1.59The company is down 18% from its price of kr1.93 on 25 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period.분석 기사 • Nov 24Prolight Diagnostics (NGM:PRLD) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is New 90 Day High Low • Nov 18New 90-day low: kr1.81The company is down 51% from its price of kr3.74 on 20 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 1.0% over the same period.Is New 90 Day High Low • Oct 21New 90-day low: kr2.24The company is down 14% from its price of kr2.61 on 23 July 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period.주주 수익률PRLDSE Medical EquipmentSE 시장7D-2.7%6.1%1.9%1Y-51.9%-4.0%12.3%전체 주주 수익률 보기수익률 대 산업: PRLD은 지난 1년 동안 -4%의 수익을 기록한 Swedish Medical Equipment 산업보다 저조한 성과를 냈습니다.수익률 대 시장: PRLD은 지난 1년 동안 12.3%를 기록한 Swedish 시장보다 저조한 성과를 냈습니다.주가 변동성Is PRLD's price volatile compared to industry and market?PRLD volatilityPRLD Average Weekly Movement11.3%Medical Equipment Industry Average Movement7.4%Market Average Movement6.3%10% most volatile stocks in SE Market13.2%10% least volatile stocks in SE Market3.7%안정적인 주가: PRLD의 주가는 지난 3개월 동안 Swedish 시장보다 변동성이 컸습니다.시간에 따른 변동성: PRLD의 주간 변동성(11%)은 지난 1년 동안 안정적이었지만 Swedish 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트199922Ulf Bladinprolightdx.com프로라이트 진단 AB(publ)는 스웨덴에서 현장 진단 검사에 사용되는 진단 시스템을 개발하는 회사입니다. 이 회사는 PLD 마이크로 플렉스 및 플렉스 멤브레인 개발에 참여하고 있습니다. 1999년에 설립되었으며 스웨덴 스톡홀름에 본사를 두고 있습니다.더 보기Prolight Diagnostics AB (publ) 기초 지표 요약Prolight Diagnostics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?PRLD 기초 통계시가총액SEK 152.97m순이익 (TTM)-SEK 49.71m매출 (TTM)SEK 42.20m3.6x주가매출비율(P/S)-3.0x주가수익비율(P/E)PRLD는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표PRLD 손익계산서 (TTM)매출SEK 42.20m매출원가SEK 0총이익SEK 42.20m기타 비용SEK 91.91m순이익-SEK 49.71m최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)-4.13총이익률100.00%순이익률-117.79%부채/자본 비율0%PRLD의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 21:04종가2026/05/21 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Prolight Diagnostics AB (publ)는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chairman of the board Fredrik Alpsten was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • Apr 22Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
분석 기사 • Dec 23Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
공시 • May 23Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million.Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million. Security Name: Shares Security Type: Common Stock Securities Offered: 501,492,480 Price\Range: SEK 0.2 Transaction Features: Rights Offering
Recent Insider Transactions Derivative • Oct 23CEO & Director exercised options to buy kr450k worth of stock.On the 18th of October, Ulf Bladin exercised options to buy 3m shares at a strike price of around kr0.12, costing a total of kr300k. This transaction amounted to 345% of their direct individual holding at the time of the trade. Since December 2023, Ulf has owned 724.64k shares directly. Company insiders have collectively bought kr358k more than they sold, via options and on-market transactions, in the last 12 months.
New Risk • Oct 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr97.4m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 75% per year over the past 5 years. Shareholders have been substantially diluted in the past year (112% increase in shares outstanding). Market cap is less than US$10m (kr97.4m market cap, or US$9.48m). Minor Risk Revenue is less than US$5m (kr25m revenue, or US$2.4m).
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chairman of the board Fredrik Alpsten was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • Apr 22Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
분석 기사 • Dec 23Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
공시 • May 23Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million.Prolight Diagnostics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 100.298496 million. Security Name: Shares Security Type: Common Stock Securities Offered: 501,492,480 Price\Range: SEK 0.2 Transaction Features: Rights Offering
Recent Insider Transactions Derivative • Oct 23CEO & Director exercised options to buy kr450k worth of stock.On the 18th of October, Ulf Bladin exercised options to buy 3m shares at a strike price of around kr0.12, costing a total of kr300k. This transaction amounted to 345% of their direct individual holding at the time of the trade. Since December 2023, Ulf has owned 724.64k shares directly. Company insiders have collectively bought kr358k more than they sold, via options and on-market transactions, in the last 12 months.
New Risk • Oct 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr97.4m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 75% per year over the past 5 years. Shareholders have been substantially diluted in the past year (112% increase in shares outstanding). Market cap is less than US$10m (kr97.4m market cap, or US$9.48m). Minor Risk Revenue is less than US$5m (kr25m revenue, or US$2.4m).
Reported Earnings • Aug 30Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr4.16m (up 32% from 2Q 2023). Net loss: kr11.2m (loss widened 40% from 2Q 2023).
공시 • Jun 25Prolight Diagnostics and TTP Provides Update on MicroFlex DevelopmentProlight Diagnostics and TTP have developed the Point-of-Care system MicroFlex which brings the benefits of central-lab quality ELISA testing to more distributed environments with a compact and more user-friendly package.
Reported Earnings • May 22First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr3.40m (down 2.7% from 1Q 2023). Net loss: kr8.93m (loss widened 18% from 1Q 2023).
공시 • Apr 19Prolight Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024Prolight Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Apr 23, 2024
공시 • Apr 10Prolight Diagnostics AB (publ), Annual General Meeting, May 14, 2024Prolight Diagnostics AB (publ), Annual General Meeting, May 14, 2024, at 13:00 Central European Standard Time. Location: Company’s office, Gasverksgatan 3 A, 222 29 Lund Sweden Agenda: To Establishment and approval of the voting list; to discuss Approval of the agenda; to discuss Election of one or two persons to verify the minutes; to Determination as to whether the Meeting has been duly convened; to Presentation of the annual report and the auditor’s report as well as the group accounts and the auditor’s report for the group for the financial year 2023; and to discuss other matters.
New Risk • Mar 04New major risk - Revenue and earnings growthEarnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Market cap is less than US$10m (kr100.0m market cap, or US$9.69m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (kr19m revenue, or US$1.8m).
New Risk • Feb 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 76% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Market cap is less than US$10m (kr100.9m market cap, or US$9.62m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (kr15m revenue, or US$1.5m).
New Risk • Dec 13New major risk - Revenue and earnings growthEarnings have declined by 36% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr49m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 36% per year over the past 5 years. Market cap is less than US$10m (kr90.6m market cap, or US$8.67m). Minor Risk Revenue is less than US$5m (kr36m revenue, or US$3.5m).
New Risk • Oct 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr83.8m (US$7.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (kr83.8m market cap, or US$7.53m). Minor Risk Revenue is less than US$5m (kr11m revenue, or US$1.0m).
분석 기사 • Jul 14Is Prolight Diagnostics (NGM:PRLD) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Jun 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (kr5.7m revenue, or US$538k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (kr120.8m market cap, or US$11.3m).
Recent Insider Transactions • Jan 22Board Member recently bought kr172k worth of stockOn the 18th of January, Tobias Volker bought around 500k shares on-market at roughly kr0.34 per share. This transaction amounted to 82% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr184k more in shares than they have sold in the last 12 months.
Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. No independent directors (6 non-independent directors). Director Maria Holmlund is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman of the Board Ingemar Kihlstrom was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • Nov 07Companies Like Prolight Diagnostics (NGM:PRLD) Can Afford To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...
분석 기사 • Jul 06We Think Prolight Diagnostics (NGM:PRLD) Can Easily Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
분석 기사 • Mar 09Companies Like Prolight Diagnostics (NGM:PRLD) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Is New 90 Day High Low • Feb 23New 90-day low: kr1.59The company is down 18% from its price of kr1.93 on 25 November 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period.
분석 기사 • Nov 24Prolight Diagnostics (NGM:PRLD) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is New 90 Day High Low • Nov 18New 90-day low: kr1.81The company is down 51% from its price of kr3.74 on 20 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Oct 21New 90-day low: kr2.24The company is down 14% from its price of kr2.61 on 23 July 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period.
